Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ubiquitin-conjugating enzyme E2I | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | ubiquitin-conjugating enzyme E2, putative | ubiquitin-conjugating enzyme E2I | 158 aa | 154 aa | 40.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | long-chain fatty-acid CoA ligase | 0.0025 | 0.251 | 0.1394 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0064 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.251 | 0.5405 |
Mycobacterium ulcerans | long-chain-fatty-acid-CoA ligase | 0.0025 | 0.251 | 0.1394 |
Giardia lamblia | UBC3 | 0.003 | 0.3541 | 0.5 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0025 | 0.251 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.251 | 0.5405 |
Toxoplasma gondii | ubiquitin-conjugating enzyme subfamily protein | 0.003 | 0.3541 | 0.1013 |
Leishmania major | ubiquitin-conjugating enzyme e2, putative | 0.003 | 0.3541 | 0.1377 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0064 | 1 | 1 |
Mycobacterium tuberculosis | Probable chain -fatty-acid-CoA ligase FadD13 (fatty-acyl-CoA synthetase) | 0.0025 | 0.251 | 0.1583 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0026 | 0.2813 | 0.6756 |
Brugia malayi | AMP-binding enzyme family protein | 0.0025 | 0.251 | 0.5934 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.2813 | 0.6756 |
Mycobacterium leprae | PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) | 0.0025 | 0.251 | 0.5 |
Brugia malayi | ube2i2 protein | 0.003 | 0.3541 | 1 |
Plasmodium falciparum | SUMO-conjugating enzyme UBC9 | 0.003 | 0.3541 | 1 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.251 | 0.1394 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.003 | 0.3541 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Mycobacterium tuberculosis | Probable fatty-acid-CoA ligase FadD2 (fatty-acid-CoA synthetase) (fatty-acid-CoA synthase) | 0.0025 | 0.251 | 0.1583 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Echinococcus granulosus | ubiquitin conjugating enzyme e2 i | 0.003 | 0.3541 | 0.3541 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Brugia malayi | AMP-binding enzyme family protein | 0.0025 | 0.251 | 0.5934 |
Echinococcus multilocularis | ubiquitin conjugating enzyme e2 i | 0.003 | 0.3541 | 0.3541 |
Onchocerca volvulus | 0.0025 | 0.251 | 0.5 | |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0026 | 0.2813 | 0.6756 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.003 | 0.3541 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0064 | 1 | 1 |
Trypanosoma brucei | ubiquitin-conjugating enzyme E2, putative | 0.003 | 0.3541 | 1 |
Mycobacterium ulcerans | fatty-acid-CoA ligase | 0.0025 | 0.251 | 0.1394 |
Chlamydia trachomatis | acylglycerophosphoethanolamine acyltransferase | 0.0019 | 0.1297 | 0.5 |
Entamoeba histolytica | ubiquitin-conjugating enzyme family protein | 0.003 | 0.3541 | 1 |
Mycobacterium tuberculosis | Fatty-acid-AMP ligase FadD30 (fatty-acid-AMP synthetase) (fatty-acid-AMP synthase) | 0.0019 | 0.1297 | 0.022 |
Leishmania major | hypothetical protein, conserved | 0.0026 | 0.2813 | 0.0405 |
Schistosoma mansoni | ubiquitin-conjugating enzyme E2 I | 0.003 | 0.3541 | 0.3541 |
Plasmodium vivax | SUMO-conjugating enzyme UBC9, putative | 0.003 | 0.3541 | 1 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.251 | 0.1394 |
Loa Loa (eye worm) | hypothetical protein | 0.0025 | 0.251 | 0.5405 |
Mycobacterium ulcerans | hypothetical protein | 0.0025 | 0.251 | 0.1394 |
Mycobacterium ulcerans | acyl-CoA synthetase | 0.0025 | 0.251 | 0.1394 |
Trypanosoma cruzi | ubiquitin-conjugating enzyme E2, putative | 0.003 | 0.3541 | 1 |
Mycobacterium ulcerans | long-chain-fatty-acid--CoA ligase | 0.0025 | 0.251 | 0.1394 |
Brugia malayi | hypothetical protein | 0.0026 | 0.2813 | 0.7129 |
Brugia malayi | AMP-binding enzyme family protein | 0.0025 | 0.251 | 0.5934 |
Loa Loa (eye worm) | ube2i2 protein | 0.003 | 0.3541 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.2813 | 0.6756 |
Trichomonas vaginalis | ubiquitin-conjugating enzyme rad6, putative | 0.003 | 0.3541 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 3.37 uM | PUBCHEM_BIOASSAY: SAR analysis of SUMOylation using HTRF in an in-Vitro dose response assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2006, AID2011, AID2018, AID2069, AID2658] | ChEMBL. | No reference |
IC50 (functional) | = 23.3 uM | PUBCHEM_BIOASSAY: SAR analysis of small molecule inhibitors of Mint-PDZ and N-type Ca2+ channel carboxyl-terminal peptide association using HTRF. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2073, AID2091, AID2093, AID434980] | ChEMBL. | No reference |
IC50 (functional) | > 56.8 uM | PUBCHEM_BIOASSAY: SAR analysis of small molecule inhibitors of Mint-PDZ and N-type Ca2+ channel carboxyl-terminal peptide association using HTRF - Set 2. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2073, AID2091, AID2093, AID2489] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.